Xell develops, produces, and sells media and feed supplements for cell cultures for use in viral vector manufacturing of gene therapies and vaccines. The company also offers analytical services for characterizing, screening, and quantifying media components, as well as media composition optimization. The privately owned company employs approximately 35 people and is expected to generate revenue of approximately 5 million euros ($5.9 million U.S.) in 2021. Xell also recently completed a facility expansion at its headquarters.

Sartorius purchased Xell for an agreed-upon price of 50 million euros ($59.4 million) in addition to two earn-out components that are contingent on the achievement of defined revenue targets in 2022 and 2025.

The acquisition expands Sartorius' offerings in specialized media for viral vectors and media analytics, it said.

Sartorius acquires majority stake in CellGenix
Life science company Sartorius has acquired a 51% stake in reagent manufacturer CellGenix through its subsidiary Sartorius Stedim Biotech.

Sartorius expands biopharma manufacturing in Slovenia
Sartorius plans to expand production facilities for purification products for vaccines and therapies at its facility in Ajdovscina, Slovenia.

Sartorius contributes to Penn State cell culture facility
Sartorius Stedim Biotech has donated $1.5 million to Pennsylvania State University (Penn State) for the creation of the Sartorius Cell Culture Facility,...

RoosterBio, Sartorius partner on cell and gene therapy manufacturing
RoosterBio and Sartorius have signed a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cell manufacturing for regenerative...